MOLECULAR MARKERS OF ENDOGENOUS NEUROPROTECTION IN THE BRAIN OF RATS WITH EXPERIMENTAL PARKINSON'S DISEASE AND ON THE BACKGROUND OF USING NEW PHARMACOTHERAPY SCHEMES

Keywords: Parkinson's disease, HIF-1α, HIF-3α, HSP70, c-fos, bcl-2, caspase-3, melatonin, neuroprotection, apoptosis

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly.

The aim of the study. To study apoptotic processes and their role in the formation of dopaminergic neurodegeneration and to develop new treatment regimens with a specific neuroprotective effect on the dopaminergic system.

Materials and methods. The study was carried out on 90 Wistar rats at the age of 6 months weighing 220–290 grams. Parkinsonism was induced by the administration of the neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to experimental rats with neuroprotective treatment: I – Intact (passive control); II – animals with experimental Parkinson's disease (PD, active control); III – PD + Amantadine (AM) IV – PD + AM + Cerebrocurin; V – PD + AM + Pramistar; VI – PD + AM + Gliatilin; VII – PD + AM + Noofen; VIII – PD + AM + Pronoran; IX – PD + AM + Melatonin.

Results. The obtained data indicate that neuroprotective therapy of PD with drugs such as melatonin, cerebrocurin, pronoran and gliatilin in combination with amantadine leads to an increase in the expression of the HIF-1α, HIF-3α, HSP70 genes, bcl-2 proteins and decrease c-fos proteins with caspase-3 as markers of apoptosis and can also serve as a molecular marker for the activation of endogenous neuroprotection mechanisms under the conditions of an experimental PD.

Conclusions. The study experimentally demonstrated a new target of neuroprotection in PD conditions – apoptosis of dopamine-producing neurons and substantiated modulators of this process – drugs for combined therapy with amantadine (melatonin, cerebrocurin, pronoran and gliatilin) ​​as promising drugs for the treatment of PD.

Downloads

Download data is not yet available.

Author Biography

Volodymyr Maramukha, State Institution "Zaporozhye Medical Academy of Postgraduate Education Ministry of Health of Ukraine"

Department of Neurology

References

Erekat, N. S. (2018). Apoptosis and its Role in Parkinson’s Disease. Parkinson’s Disease: Pathogenesis and Clinical Aspects, 65–82. doi: https://doi.org/10.15586/codonpublications.parkinsonsdisease.2018.ch4

Sadlon, A., Takousis, P., Alexopoulos, P., Evangelou, E., Prokopenko, I., Perneczky, R. (2019). miRNAs Identify Shared Pathways in Alzheimer’s and Parkinson’s Diseases. Trends in Molecular Medicine, 25 (8), 662–672. doi: https://doi.org/10.1016/j.molmed.2019.05.006

Yuan, J., Amin, P., Ofengeim, D. (2018). Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nature Reviews Neuroscience, 20 (1), 19–33. doi: https://doi.org/10.1038/s41583-018-0093-1

Gelders, G., Baekelandt, V., Van der Perren, A. (2018). Linking Neuroinflammation and Neurodegeneration in Parkinson’s Disease. Journal of Immunology Research, 2018, 1–12. doi: https://doi.org/10.1155/2018/4784268

Larsen, S. B., Hanss, Z., Krüger, R. (2018). The genetic architecture of mitochondrial dysfunction in Parkinson’s disease. Cell and Tissue Research, 373 (1), 21–37. doi: https://doi.org/10.1007/s00441-017-2768-8

Jiang, P., Dickson, D. W. (2017). Parkinson’s disease: experimental models and reality. Acta Neuropathologica, 135 (1), 13–32. doi: https://doi.org/10.1007/s00401-017-1788-5

Bohush, A., Niewiadomska, G., Filipek, A. (2018). Role of Mitogen Activated Protein Kinase Signaling in Parkinson’s Disease. International Journal of Molecular Sciences, 19 (10), 2973. doi: https://doi.org/10.3390/ijms19102973

Horvath, I., Iashchishyn, I. A., Moskalenko, R. A., Wang, C., Wärmländer, S. K. T. S., Wallin, C. et. al. (2018). Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson’s disease: ex vivo and in vitro studies. Journal of Neuroinflammation, 15 (1). doi: https://doi.org/10.1186/s12974-018-1210-9

Ma, C., Pan, Y., Yang, Z., Meng, Z., Sun, R., Wang, T. et. al. (2016). Pre-administration of BAX-inhibiting peptides decrease the loss of the nigral dopaminergic neurons in rats. Life Sciences, 144, 113–120. doi: https://doi.org/10.1016/j.lfs.2015.11.019

Belenichev, I., Burlaka, B., Puzyrenko, A., Ryzhenko, O., Kurochkin, M., Yusuf, J. (2019). Management of amnestic and behavioral disorders after ketamine anesthesia. Georgian medical news, 294, 141–145.


👁 10
⬇ 3
Published
2020-10-29
How to Cite
Maramukha, V. (2020). MOLECULAR MARKERS OF ENDOGENOUS NEUROPROTECTION IN THE BRAIN OF RATS WITH EXPERIMENTAL PARKINSON’S DISEASE AND ON THE BACKGROUND OF USING NEW PHARMACOTHERAPY SCHEMES. Technology Transfer: Innovative Solutions in Medicine, 31-33. https://doi.org/10.21303/2585-663.2020.001491
Section
Medicine and Dentistry